Revised Consensus Clinical Trial Response Criteria by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology
Year: 2026
Type: article
Abstract: Invasive fungal diseases remain a significant cause of patient morbidity and mortality. Improvement in clinical outcomes have been the result of progress in risk stratification, diagnostics, adjunctive care, antifungal therapy, and/or prophylaxis. Yet significant challenges remain, requiring the development of novel treatment strategies. Outcome evaluation in most mycology clinical trials is currently based on consensus criteria published in 2008. However, advances in diagnosis and management of various mycoses and the ever-expanding population of patients at risk necessitate a revision and refinement of these criteria. Appropriate categorization of antifungal treatment response is crucial in assessing the effects of new therapeutic interventions. An international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened to update the current outcome evaluation criteria. The panel achieved consensus on updated guidelines for assessing treatment responses and defining study outcomes in clinical trials of aspergillosis and other mold diseases, invasive candidiasis, cryptococcosis, and dimorphic fungi in both adults and children. This summary manuscript provides details on the methods, outlines key changes in the criteria, and discusses the next steps and areas for future research.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag579
Authors: Martin Hoenigl, George R Thompson, Peter G Pappas, Oliver A Cornely, John R Perfect, Neil A R Gow, Dimitrios P Kontoyiannis, Cornelia Lass-Flörl, Johan Maertens, Monica A Slavin, Jean-Pierre Gangneux, Marisa H Miceli, Patricia Munoz, Ana Alastruey-Izquierdo, Tihana Bicanic, David R Boulware, Jose A Vazquez, Sevtap Arikan-Akdagli, Carolynn T Jones, Luis Ostrosky-Zeichner
Institutions: Medical University of Graz, BioTechMed-Graz, University of California Davis Medical Center, University of California, Davis, University of Alabama at Birmingham, UAB Medicine, University of Cologne, German Center for Infection Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Duke University, Duke Medical Center, University of Exeter, MRC Centre for Medical Mycology, The University of Texas MD Anderson Cancer Center, Innsbruck Medical University, Universität Innsbruck, Universitair Ziekenhuis Leuven, KU Leuven, The University of Melbourne, Peter MacCallum Cancer Centre, Inserm, Institut de Recherche en Santé, Environnement et Travail, Centre Hospitalier Universitaire de Rennes, Université de Rennes, University of Michigan, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Centro de Investigación Biomédica en Red, Instituto de Investigación Sanitaria Gregorio Marañón, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, City St George's, University of London, University of Minnesota, Augusta University, Hacettepe University, The Ohio State University, The University of Texas Health Science Center at Houston
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
OpenAlex ID: W7235383072
